Enzomenib might be the most promising agent so far, on a cross-trial basis.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

Kura will see more combo data, while a new contender from Sumitomo emerges.

First-in-human trial initiations feature Interius, Umoja and Vironexis.